Ken Griffin Voyager Therapeutics, Inc. Transaction History

Citadel Advisors LLC

$509 Billion
Q1 2025

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Voyager Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 12,900 shares of VYGR stock, worth $40,635. This represents 0.0% of its overall portfolio holdings.

Number of Shares

12,900

Previous 6,000 115.0%

Holding current value

$40,635

Previous $34,000 26.47%

% of portfolio

0.0%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	BUY	$3.38 - $6.04 $226,632 - $404,988	67,051 Added 1884.51%	70,609 $238,000
Q4 2024 Feb 14, 2025	SELL	$5.27 - $8.07 $1.29 Million - $1.97 Million	-244,078 Reduced 98.56%	3,558 $20,000
Q3 2024 Nov 14, 2024	BUY	$5.77 - $9.27 $761,911 - $1.22 Million	132,047 Added 114.24%	247,636 $1.45 Million
Q2 2024 Aug 14, 2024	BUY	$7.42 - $10.54 $660,847 - $938,724	89,063 Added 335.76%	115,589 $914,000
Q1 2024 May 15, 2024	BUY	$7.15 - $10.84 $189,660 - $287,541	26,526 New	26,526 $246,000
Q3 2023 Nov 14, 2023	SELL	$7.55 - $11.25 $1.45 Million - $2.16 Million	-191,910 Reduced 86.92%	28,885 $223,000
Q2 2023 Aug 14, 2023	BUY	$6.94 - $13.99 $813,937 - $1.64 Million	117,282 Added 113.3%	220,795 $2.53 Million
Q1 2023 May 15, 2023	SELL	$6.0 - $10.78 $350,424 - $629,595	-58,404 Reduced 36.07%	103,513 $798,000
Q4 2022 Feb 14, 2023	SELL	$4.94 - $6.61 $299,067 - $400,169	-60,540 Reduced 27.21%	161,917 $987,000
Q3 2022 Nov 14, 2022	BUY	$5.57 - $7.47 $777,778 - $1.04 Million	139,637 Added 168.6%	222,457 $1.32 Million
Q2 2022 Aug 15, 2022	SELL	$4.82 - $10.09 $275,573 - $576,875	-57,173 Reduced 40.84%	82,820 $490,000
Q1 2022 May 16, 2022	BUY	$2.75 - $9.44 $197,180 - $676,866	71,702 Added 104.99%	139,993 $1.07 Million
Q4 2021 Feb 14, 2022	SELL	$2.47 - $5.55 $2.26 Million - $5.08 Million	-914,533 Reduced 93.05%	68,291 $185,000
Q3 2021 Nov 15, 2021	SELL	$2.63 - $4.12 $1.64 Million - $2.57 Million	-623,670 Reduced 38.82%	982,824 $2.59 Million
Q2 2021 Aug 16, 2021	BUY	$3.94 - $5.44 $5.37 Million - $7.42 Million	1,363,816 Added 561.99%	1,606,494 $6.63 Million
Q1 2021 May 17, 2021	SELL	$4.61 - $9.04 $2.73 Million - $5.35 Million	-591,274 Reduced 70.9%	242,678 $1.14 Million
Q4 2020 Feb 16, 2021	SELL	$7.15 - $12.28 $35,220 - $60,491	-4,926 Reduced 0.59%	833,952 $5.96 Million
Q3 2020 Nov 16, 2020	BUY	$10.01 - $13.75 $3.14 Million - $4.32 Million	314,120 Added 59.86%	838,878 $8.95 Million
Q2 2020 Aug 14, 2020	BUY	$8.05 - $14.21 $3.29 Million - $5.8 Million	408,507 Added 351.4%	524,758 $6.62 Million
Q1 2020 May 15, 2020	SELL	$6.8 - $14.66 $2.6 Million - $5.6 Million	-382,157 Reduced 76.68%	116,251 $1.06 Million
Q4 2019 Feb 14, 2020	BUY	$12.82 - $16.85 $1.28 Million - $1.69 Million	100,161 Added 25.15%	498,408 $6.95 Million
Q3 2019 Nov 14, 2019	BUY	$16.31 - $28.29 $4.17 Million - $7.23 Million	255,536 Added 179.06%	398,247 $6.85 Million
Q2 2019 Aug 14, 2019	BUY	$19.18 - $27.88 $2.13 Million - $3.1 Million	111,092 Added 351.35%	142,711 $3.89 Million
Q4 2018 Feb 14, 2019	SELL	$8.59 - $18.05 $177,735 - $373,472	-20,691 Reduced 39.55%	31,619 $297,000
Q3 2018 Nov 13, 2018	SELL	$17.11 - $21.74 $415,653 - $528,129	-24,293 Reduced 31.71%	52,310 $0
Q1 2018 May 11, 2018	SELL	$16.16 - $31.31 $312,437 - $605,347	-19,334 Reduced 20.15%	76,603 $1.44 Million
Q4 2017 Feb 09, 2018	SELL	$12.26 - $25.88 $1.89 Million - $4 Million	-154,447 Reduced 61.68%	95,937 $1.59 Million
Q3 2017 Nov 09, 2017	BUY	$8.37 - $20.59 $2.1 Million - $5.16 Million	250,384	250,384 $5.16 Million

Others Institutions Holding VYGR

# of Institutions

119

Shares Held

34.5M

Call Options Held

12.9K

Put Options Held

37.7K

View Full List

About Voyager Therapeutics, Inc.

Ticker VYGR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,647,600
Market Cap $122M
Description
Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyo...

More about VYGR

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account